CTNM
Contineum Therapeutics, Inc.
Key Financials
Net Income
$-59978000
↓ 41.9%
Revenue
$0
↓ 100.0%
Operating Income
$-68059000
↓ 33.7%
Total Liabilities
$15.7M
↑ 5.9%
EPS (Diluted)
$-2.17
↑ 0.5%
Shareholders' Equity
$261.0M
↑ 31.8%
Total Assets
$276.6M
↑ 30.0%
Cash & Equivalents
$75.6M
↑ 244.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 10/1/2026 | View on SEC |
| 8-K | 9/14/2026 | View on SEC |
| 4 | 9/8/2026 | View on SEC |
| 144 | 9/8/2026 | View on SEC |
| 144 | 9/1/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 4 | 8/3/2026 | View on SEC |
| 144 | 8/3/2026 | View on SEC |
| 144 | 8/3/2026 | View on SEC |
| 10-Q | 7/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CTNM |
| Company Name | Contineum Therapeutics, Inc. |
| CIK | 1855175 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 333-5280 |